CompoAtlas

AJO ESPINO OLIVO

Food supplement declared in France, decision dated 6 January 2026

AJO ESPINO OLIVO (CFN) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Olea europaea 200 mg per day, Crataegus laevigata 200 mg per day, Allium sativum 100 mg per day. None of the rules we check flags an issue with its declared composition.

Brand
CFN
Food business operator placing the product on the market
Complementos fitonutricionales SL
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Capsule
Daily dose
1 perle
Directions for use
Prendre 1 perle par jour avec un demi-verre d'eau (125 ml) ou selon les recommandations d'un professionnel.
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, Pregnant women, Kidney failure, Heart problems, Taking anticoagulants

Declaration 350753, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Olea europaea L.FeuilleMacérât huileux200 mg
Crataegus laevigata (Poir.) DC.FruitMacérât huileux200 mg
Allium sativum L.BulbeMacérât huileux100 mg

Additives

E422

Other ingredients

Gélatine bovine

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Les compléments alimentaires ne soient utilisés comme substituts d'un régime alimentaire varié. Il est nécessaire de maintenir une alimentation variée et équilibrée et un mode de vie sain. Ne pas dépasser la dose journalière expressément recommandée. Les produits doivent être tenus hors de la portée des jeunes enfants. Conserver dans un endroit sec, frais et à l'abri de la lumière directe. Déconseillé en cas d'insuffisance cardiaque ou rénale. Réservé aux adultes. Déconseillé aux femmes enceintes et allaitantes. Son utilisation est déconseillée chez les personnes sous traitement anticoagulant.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Olea europaea L.
    Read the warning, when it applies and the studies cited

    OLIVE LEAF - OLEA EUROPAEA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you pregnant or breastfeeding (EMA 2017).

    Sources cited by Health Canada (1)
    • EMA 2017: European Medicines Agency. European Union herbal monograph on Olea europaea L., folium. [Accessed 2024 November 27]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder (EMA 2017).

    Sources cited by Health Canada (1)
    • EMA 2017: European Medicines Agency. European Union herbal monograph on Olea europaea L., folium. [Accessed 2024 November 27]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking other diuretics (EMA 2017).

    Sources cited by Health Canada (1)
    • EMA 2017: European Medicines Agency. European Union herbal monograph on Olea europaea L., folium. [Accessed 2024 November 27]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf

    Known adverse reactions

    Condition of application: All products except those making a diuretic claim.

    When using this product diuretic effect may occur.

    Health Canada monograph dated 19 December 2025

  • Crataegus laevigata (Poir.) DC.
    Read the warning, when it applies and the studies cited

    Hawthorn

    Route of administration: Oral (ESCOP 2009; Bradley 2006; Mills and Bone 2000)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking cardiac glycosides (e.g., digoxin) or blood pressure or heart medications (Brinker 2010; Bradley 2006).

    Sources cited by Health Canada (2)
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have chest pain, irregular heartbeat, or shortness of breath.

    Health Canada monograph dated 31 July 2026

  • Allium sativum L.
    Read the warning, when it applies and the studies cited

    Garlic - Allium sativum

    Route of administration: Oral

    Cautions and warnings

    Condition of application: Relief of upper respiratory tract infections and catarrhal (nasal congestion) conditions.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or protease inhibitors (Brinker 2010; Mills and Bone 2005).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Brinker 2010; Mills and Bone 2005).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Mills and Bone 2005).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (Brinker 2010; Mills and Bone 2005).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Health Canada monograph dated 30 January 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : CFN

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “AJO ESPINO OLIVO (CFN): composition and regulation”, https://compoatlas.com/en/supplements/products/350753-ajo-espino-olivo, updated 15 November 2026.

Enter to analyse, Shift+Enter for a new line